← Human Trials & Peer-Reviewed Studies
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Plain-language guide to NCT06579105: phase 2 randomized trial of Semaglutide, 406 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06579105
- Phase
- phase 2
- Status
- completed
- Start
- 2024-10-08
- Completion (planned or actual)
- 2025-12-19
- Participants
- 406 (actual)
- Design
- randomized, triple-blind, treatment
- Conditions studied
- Diabetes Mellitus, Type 2
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 2 trial tested Semaglutide.
It had eight arms (groups): Arm 1 (experimental), Arm 2 (experimental), Arm 3 (experimental), Arm 4 (experimental) and Arm 5 (experimental).
The registry classes the interventions as drug.
More on the Plan
The study is planned to be conducted in approximately 15 countries, approximately 90 sites will be involved.
Who Took Part
Enrollment: 406 actual participants took part.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
How the Study Was Run
It was run as a randomized, parallel-group and triple-blind study.
Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Semaglutide group and the comparison group ran side by side rather than switching.
Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.
Those kept unaware of assignments: participant, care provider and investigator.
It started in 2024-10-08 with completion listed for 2025-12-19.
It ran at 97 sites in United States (50), Poland (8), Spain (7), United Kingdom (7), Canada (6) and Germany (6).
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Change in HbA1c (time frame: Baseline to Week 26).
It also tracked 6 secondary outcomes, for example Change in fasting glucose, Percent change in body weight and Absolute change in body weight.
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Semaglutide in 406 people.
The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.